Pulse BiosciencesPLSE
Recorded

Pulse Biosciences 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 19 minParticipants10

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Thank you for standing by. My name is Cath, and I will be your conference operator today. At this time, I would like to welcome everyone to the Pulse Biosciences Third Quarter 2026 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be question and answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the call over to Tripp Taylor, Investor Relations.

Tripp TaylorHead of Investor Relations

Please go ahead. Thank you, operator.

Tripp TaylorHead of Investor Relations

Before we begin, I'd like to inform you that comments and responses to your questions during today's call reflect management's views as of today, November 5, 2026, only, and will include forward-looking statements and opinion statements, including predictions, estimates, plans, expectations, and other similar information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued today and in our filings with the U.S. Securities and Exchange Commission. Our SEC filings can be found on our website or on the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. We disclaim any obligation to update or revise these forward-looking statements. We will also discuss certain non-GAAP financial measures.

Tripp TaylorHead of Investor Relations

Disclosures regarding these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that this conference call will be available for audio replay on our website at pulsebiosciences.com in the News and Events section on our Investor Relations page. With that, I would now like to turn the call over to Co-Chair of the Board and Chief Executive Officer, Paul LaViolette.

Paul LaVioletteCo-Chair of the Board and CEO

Thank you, Tripp. Good afternoon, and thank you, everyone, for joining us today to discuss our third quarter 2026 results and business progress. The team at Pulse Biosciences delivered a strong quarter, and we are looking forward to creating continued momentum in Q4 and into 2027. I will begin by describing the technology at the core of everything we do at Pulse Biosciences, our proprietary nanosecond pulsed field ablation energy, or nsPFA technology. nsPFA produces a fundamentally unique form of non-thermal ablation energy with a differentiated mechanism of action to treat cells. Because our pulses last only billionths of a second, there is virtually no energy deposition that converts to heat and almost no rise in the temperature of the tissue being treated or to adjacent areas.

Paul LaVioletteCo-Chair of the Board and CEO

The unique nsPFA energy acts on the membranes of the structures inside the cell, causing the cell to undergo regulated cell death without unwanted inflammatory responses. In addition, this energy is delivered very efficiently. High-efficiency energy delivery allows our catheter system to produce cardiac ablation lesions in tissue that are larger, deeper, and more consistent than lesions created with early-generation PFA systems. The combination of highly efficient lesion production and a very effective ablation mechanism of action results in a non-thermal ablation with exceptional procedural workflow efficiency, very reliable lesion formation, and minimized risk of collateral tissue injury. This mechanism is unique to nsPFA and is substantially different from that produced by thermal energies or by the broad category of first-generation microsecond PFA alternatives.

Paul LaVioletteCo-Chair of the Board and CEO

As the pioneer in this field, we are the developmental source of this energy technology, as well as the delivery systems that enable its wide array of clinical applications, and we protect this platform with over 285 owned patents. This patent moat, together with the more than a decade amassing dedicated technical know-how, protects our long-term leadership in this field. We are the first, we are the best, and at this point in time, we are the only source of nsPFA for the foreseeable future. The third quarter was a period of strong execution in both our clinical and financial capital formation programs. On the clinical front, we announced in early October that NANOPULSE-AF, our U.S. pivotal IDE study of the nPulse Cardiac Catheter, reached its enrollment target of evaluable patients, completing this critically important phase of the study.

Paul LaVioletteCo-Chair of the Board and CEO

We completed enrollment in less than six months, nicely exceeding the forecasted pace of our original enrollment timeline of nine months. We believe this pace was the result of exceptional physician enthusiasm stemming from the demonstrated safety, efficacy, and workflow differentiation of the technology. We are extremely proud of the PulseBio team and this accomplishment. On the financial front, we ended the quarter with cash and marketable securities of $189 million, comfortably supporting our operating goals with approximately two years of cash runway. Our ATM program has raised more than $150 million in net proceeds since May, and we are proud to have raised this capital at low cost and with increasing equity value, with cumulative dilution of under 6%. We view the strength of our balance sheet as a strategic asset.

Paul LaVioletteCo-Chair of the Board and CEO

It positions us to fund our programs through key clinical and regulatory milestones, and to make strategic operational investments that will strengthen our catheter launch readiness. Clearly, we continue to have favorable access to capital, and Jon Skinner will discuss our remaining ATM capacity later on in this call. Now, we will discuss our cardiac catheter program in greater detail, then I will provide updates on our surgical clamp and Vybrance programs. We will then turn the call over to our Chief Financial Officer, Jon Skinner, to review the third quarter financial results in detail. We will conclude with a question-and-answer session joined by Bob Duggan, Co-Chair of the Board. I will now discuss the nPulse Cardiac Catheter system designed to fundamentally improve current catheter-based treatments for atrial fibrillation.

Paul LaVioletteCo-Chair of the Board and CEO

In early October, we shared that the NANOPULSE-AF study completed enrollment for evaluable patients, net of roll-ins, which occurred across 15 clinical sites with 36 investigators. We concluded study enrollment with 169 evaluable patients and 189 total patients, including 20 roll-ins. Our study enrolled with rapid velocity and finished three months ahead of the originally communicated timeline. We could not be more pleased with the collaboration established between our Pulse Biosciences team and the clinical investigators and site teams that enabled us to achieve this extraordinary enrollment accomplishment. As expected, what we have observed in the study has reinforced our procedural observations in the European feasibility study. Physicians commented, and our team members observed directly in every case, that the nPulse Cardiac Catheter system was extremely intuitive to use, with minimal learning curve, and offered seamless workflow integration.

Paul LaVioletteCo-Chair of the Board and CEO

This was observable in site after site, as dozens of electrophysiologists used the nPulse system for the first time in the pivotal study. The nPulse Cardiac Catheter is designed to complete isolation with a single five-second delivery per location, with no need to reposition the catheter or overlap lesions. Our patented flexible electrodes conform to the anatomy, providing physicians the ease of maneuverability to place the catheter accurately and quickly, and to hold it stably while delivering therapy. Because nsPFA is so efficient, total energy delivery is low, nerve and muscle stimulation is very limited, tissue is not heated, and there is no waiting time between deliveries. These factors combine to allow physicians to move quickly and confidently from one vein to the next without delay, as they complete pulmonary vein isolation with unmatched expediency, as well as confidence in its outcomes, safety, and precision.

Paul LaVioletteCo-Chair of the Board and CEO

This technique differentiation translates into clinical efficiency, and in several cases, we observed physicians perform their first case with ablation times in under seven minutes, which is unusually efficient when compared to any available ablation system. Our Chief Medical Officer, Dr. David Kenigsberg, described the pattern at our sites well. Once operators did one case, they were amazed and eager to treat more patients. Dr. Vivek Reddy from Mount Sinai Fuster Heart Hospital and national PI on the trial noted that NANOPULSE-AF was one of the fastest enrolling trials he has seen or participated in. Dr. Shephal Doshi of Pacific Heart Institute described his early experience with the nPulse system as potentially transformative, pointing to the catheter design and its one-shot approach. With enrollment completed, all patients are now in follow-up.

Paul LaVioletteCo-Chair of the Board and CEO

As a reminder, our efficacy endpoint, freedom from treatment failure through 12 months, incorporates a mix of 12-month and six-month follow-up data. Based on that follow-up plan, we expect to receive final patient data based on the blended six-month and 12-month follow-up in Q3 2027, and to convert that data into the final clinical module for PMA submission. We are actively working on our FDA and CE regulatory submissions processes and have commenced modular submissions. We also anticipate CE Mark approval occurring in Q4 of 2027. Our European feasibility results have made a powerful statement about the clinical efficacy potential of nsPFA, and we believe the growing dataset from Europe will be informative of future IDE results. The EU dataset features the same catheter, the same energy settings, the same paroxysmal AF enrollment criteria, and even some of the same operators as in the IDE.

Paul LaVioletteCo-Chair of the Board and CEO

E.U. feasibility enrollment has now reached more than 190 patients in total and over 155 patients in the five-second cohort. We intend to submit these data for presentation at the AF Symposium in early 2027, which will include more than 100 patients with 12-month follow-up. As a reminder, at Heart Rhythm Society, or HRS, in April of this year, Dr. Vivek Reddy, national principal investigator of our pivotal study, presented expanded results from our European nPulse Cardiac Catheter feasibility study. The data reported on the five-second ablation cohort with 12-month follow-up on 53 patients. The results were outstanding. Freedom from AF, measured by 24-hour Holter monitor, was 96% at one year. Kaplan-Meier estimated freedom from recurrent atrial fibrillation, flutter, or tachycardia was 90% at one year.

Paul LaVioletteCo-Chair of the Board and CEO

Given the breakthrough level of efficacy reported to date and the volume of patient data to be reported, over 100 patients followed 12 months during Q1 2027, we believe those data will be very informative of the nPulse system's potential to establish significant share penetration of the AF ablation market upon commercial launch. I want to spend a moment on our strategic outlook for 2026 and beyond. With the nPulse Cardiac Catheter IDE fully enrolled, our focus now shifts to pre-commercial readiness in addition to regulatory submissions. We intend to build a strong foundation to support commercial launches and broad market adoption. These initiatives include supply chain planning, market access planning, marketing and customer segmentation planning. We'll support virtually any form of launch or partnership and accelerate our preparedness to support a launch beginning in early 2028.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day